Regulatory support for bitox, a detoxified form of botulism neurotoxin (BONT), as a treatment for chronic neuropathic pains focusing on osteoarthritis, a degenerative joint disease.

Ended Awarded Last action

Contract number
75N95023F00001
Awardee
Awarding agency
Obligated
$79,269

Award facts

Contract value 12% obligated
  • $79,268.84 Current, with exercised options
  • $654,181.14 Potential, with all options
Completion date 100% complete
  • Current, with exercised options
  • Potential, with all options
Funding agency
National Center for Advancing Translational Sciences National Institutes of Health, Department of Health and Human Services
Set-aside
No set-aside
Competition
Full and Open Competition after exclusion of sources · 3 offers Multiple Award, Fair Opportunity
Pricing
Labor Hours
Place of performance
Philadelphia, PA 19102, USA
Legislative mandates

Award details come from SAM.gov/FPDS.

Transactions

Action Obligated Date
Other Administrative Action P00002 $0
Supplemental Agreement for work within scope P00001 $5,222
Original award $74,047

About this award

The National Center for Advancing Translational Sciences (NCATS) awarded a delivery order valued at $654,181 to MPF Federal, LLC on September 22, 2023, for regulatory support services related to BITOX, a detoxified form of botulism neurotoxin (BoNT) intended as a therapeutic treatment for chronic neuropathic pain, with a specific focus on osteoarthritis and other degenerative joint diseases. The contract, which extends through September 21, 2026, is structured as a labor-hour engagement with no set-aside designation, though MPF Federal qualifies for multiple socioeconomic certifications including Economically Disadvantaged Women-Owned Small Business (EDWOSB), 8(a) Program Participant, Women-Owned Small Business, and HUBZone firm status. Work will be performed in Middle City East, Pennsylvania.

MPF Federal, LLC, a small business headquartered in Gaithersburg, Maryland, is well-positioned to deliver this regulatory support through its extensive experience in clinical studies management, regulatory consulting, and quality assurance services across federal agencies. The award derives from MPF Federal's $19.3 million Indefinite Delivery/Indefinite Quantity (IDIQ) contract with NCATS, which enables the company to provide professional services supporting translational science initiatives. The regulatory support services under this delivery order will likely facilitate the advancement of BITOX through the appropriate regulatory pathways, supporting NCATS's mission to accelerate the translation of laboratory discoveries into treatments for patients.

Quick answers

Who was awarded contract 75N95023F00001?

75N95023F00001 was awarded to MPF Federal, LLC by National Institute on Drug Abuse (National Institutes of Health) on September 22, 2023.

How much is contract 75N95023F00001 worth?

The government has obligated $79,269 on 75N95023F00001. Its potential value, with all options, is $654,181.

Which agency awarded contract 75N95023F00001?

National Institute on Drug Abuse (National Institutes of Health) awarded 75N95023F00001, with funding from National Center for Advancing Translational Sciences (National Institutes of Health).

Is contract 75N95023F00001 an order under another contract?

Yes. 75N95023F00001 is a delivery order under 75N95022D00014, an indefinite delivery contract.

Was contract 75N95023F00001 competed?

The extent of competition for 75N95023F00001 was full and open competition after exclusion of sources. The government received 3 offers.

On GovTribe

See this award's full record

  • Every transaction and funding action
  • The awardee's other awards and teaming partners
  • Similar awards and recompete opportunities
  • Ask GovTribe AI about this award